Where Private Equity Litigation Comes From and How to Limit It

What Makes Private Equity Litigation Different from Ordinary Investment Disputes

Private equity litigation is not a retail investor problem. When you're committing $5M or more to a fund, you're operating in a world where disputes routinely involve nine-figure valuations, multi-year discovery processes, and legal theories that don't appear in any standard investment advisory disclosure. Global private equity assets under management exceeded $8 trillion as of 2024, according to Preqin, and the legal conflict that accompanies that scale has grown proportionally. Understanding where disputes originate, how they develop, and how to structure your exposure before signing an LP agreement is the actual work.

The standard guidance written for institutional allocators doesn't map cleanly onto a high-net-worth individual with a concentrated PE portfolio. Your exposure profile is different. Your negotiating leverage is different. And the litigation risks you face as a direct co-investor or secondary buyer are categorically distinct from those facing a pension fund with a dedicated legal team reviewing every capital call.

What Are the Most Common Causes of Private Equity Litigation?

Five dispute categories generate the overwhelming majority of private equity litigation. Knowing which structures create which risks lets you screen funds before you commit.

Breach of fiduciary duty sits at the top of the list. GPs owe fiduciary duties to the fund and, by extension, to LPs. Claims arise when GPs allegedly self-deal, favor one fund over another in a co-investment allocation, or make decisions that benefit the management company at the expense of fund performance. The Delaware Court of Chancery remains the dominant venue for resolving these disputes, given that most PE funds and portfolio companies are Delaware-domiciled entities. The court's appraisal and fiduciary duty jurisprudence, illustrated in cases like In re Dell Technologies Inc. Class V Stockholders Litigation (2022), sets the framework that practitioners actually use.

Valuation disputes are the second major category. LPs allege that GPs inflated portfolio company marks to boost management fees or delay the recognition of losses. These cases require competing expert testimony on fair value methodology and can run for years.

Conflicts of interest have become the SEC's stated enforcement priority. The SEC's 2024 examination priorities for private fund advisers specifically identify undisclosed conflicts, fee and expense practices, and Investment Advisers Act compliance as top concerns. When the regulator is already looking at these issues, LP litigation following the same theories becomes easier to pursue.

Fraud and misrepresentation claims, while less common, carry the highest stakes. See fraudulent practices in PE for a detailed breakdown of how these cases typically develop.

Contractual disputes over carried interest calculations, distribution waterfalls, and clawback obligations round out the list. IRC Section 1061, as amended by the Tax Cuts and Jobs Act, imposes a three-year holding period for carried interest to qualify for long-term capital gains treatment, and disputes over its application between GPs and LPs have become a recurring source of fund-level conflict.

How GP-Led Secondaries Have Become the Fastest-Growing Litigation Risk

This is the area where the standard LP-GP conflict framework breaks down most visibly, and where high-net-worth investors are disproportionately exposed.

GP-led secondary transactions, where a GP moves assets from an existing fund into a continuation vehicle rather than returning capital at fund end, represented approximately $50 billion in transaction volume in 2023, according to Evercore's secondary market survey. The structure creates a textbook conflict: the GP simultaneously represents the selling fund (existing LPs who want liquidity) and the buying continuation vehicle (new investors who want the asset). There is no independent party setting the price.

Debevoise & Plimpton's quarterly PE report has identified continuation fund transactions and GP-led secondaries as among the highest-litigation-risk structures in the market, specifically because of the conflict between GPs and existing LPs over valuation and consent rights.

For a high-net-worth investor in a later-vintage fund, the practical problem is this: you may face a choice between rolling your position into the continuation vehicle at a GP-determined valuation or accepting a liquidity option at a price you cannot independently verify. If you roll, you're now in a new fund with different terms. If you take liquidity, you may be leaving value on the table. Either way, your ability to challenge the process after the fact is constrained by the consent mechanics in your original LP agreement.

The mitigation is front-loaded. Before committing to any fund that is likely to generate assets worth holding beyond the standard fund life, review the LP agreement's provisions on GP-led restructurings, consent thresholds, and fairness opinion requirements. The SEC's 2023 Private Fund Rules, before being vacated by the Fifth Circuit in June 2024, had imposed fairness opinion requirements on continuation fund transactions. The rules were struck down, but the SEC's enforcement posture on undisclosed conflicts in these structures has not changed.

How LP Agreements Limit Investor Rights to Sue General Partners

Most LP agreements are written by GP counsel. That is not a cynical observation; it is a structural reality that shapes every provision you will rely on if a dispute arises.

The American Bar Association's Business Law Section has documented that indemnification provisions and exculpation clauses in limited partnership agreements are the primary contractual mechanisms GPs use to limit litigation exposure from LP claims. Standard exculpation language typically limits GP liability to acts constituting gross negligence, willful misconduct, or fraud. Ordinary negligence, poor judgment, and even significant conflicts of interest may fall outside the scope of actionable claims under a heavily GP-favorable agreement.

The practical implication: the contractual floor for GP conduct is lower than most LPs assume when they sign.

Delaware's implied covenant of good faith and fair dealing provides a partial counterweight. Courts have found that GPs cannot use broad contractual discretion to act in a manner that destroys the reasonable expectations of LPs at the time of contracting. This doctrine has been successfully invoked in valuation and distribution timing disputes, and it remains a viable claim even in heavily GP-favorable fund structures. The key point is that contractual exculpation does not fully foreclose litigation.

ILPA's Principles 3.0 establish industry best practices for LP agreement terms, including key-man provisions, no-fault divorce clauses, and fee offset requirements. The absence of ILPA-aligned provisions in a fund's LP agreement is a concrete signal of GP-favorable governance and a predictor of future disputes.

Review key contractual elements before signing any LP agreement, and treat the gap between ILPA standards and the fund's actual terms as a quantified risk factor, not a negotiating footnote.

What Due Diligence Should a $5M+ Investor Perform to Avoid Litigation Risk?

The due diligence that matters for litigation risk is not the same as the due diligence that matters for return analysis. Most fund marketing materials will not surface the information you need.

Start with the GP's litigation history. Request a complete disclosure of all material legal proceedings involving the GP, its principals, and its prior funds. The SEC's EDGAR system and court dockets in Delaware and New York are searchable. A GP with a pattern of LP disputes is a different risk profile than one with a clean record, regardless of how the fund's IRR looks on paper.

Review the fund's audit and due diligence procedures for portfolio company valuations. Ask specifically who performs independent valuation reviews, how frequently, and whether the methodology is consistent across reporting periods. Valuation disputes are easier to prevent than to litigate.

Examine the insurance stack at both the fund and portfolio company levels. Directors and Officers (D&O) insurance and representations and warranties (R&W) insurance have become standard in PE-backed M&A transactions above $100M. Many individual LP investors and co-investors fail to confirm whether portfolio company-level insurance adequately covers indemnification obligations that could otherwise flow back to the fund and affect LP returns. Ask for confirmation of D&O coverage limits, tail periods, and whether the fund itself carries E&O coverage.

Assess governance best practices by reviewing the LP Advisory Committee structure. An LPAC with real authority over conflict approvals, related-party transactions, and valuation methodology is a material risk mitigant. An LPAC that exists on paper but has no binding consent rights is not.

Finally, review the GP's side letter practices. The SEC has documented that preferential side letter terms negotiated by larger LPs, including fee breaks, co-investment rights, and enhanced information rights, can themselves become litigation flashpoints if not uniformly disclosed to other LPs. Ask whether the fund has a most-favored-nation clause and whether it is self-executing or requires you to affirmatively request parity.

What Legal Protections Do Co-Investors Have in Private Equity Deals?

Co-investment is where high-net-worth individuals most frequently encounter PE litigation risk without the institutional infrastructure to manage it.

When you co-invest alongside a fund in a specific portfolio company, you typically hold a direct equity stake governed by a separate co-investment agreement rather than the main fund's LP agreement. The protections available to you depend entirely on what that agreement says, and co-investment agreements are almost always less LP-protective than the main fund documents.

Common gaps in co-investment agreements include: no information rights beyond what the GP chooses to share, no independent board representation, limited or no consent rights over material transactions affecting the portfolio company, and broad indemnification running in favor of the GP. Understanding acquisition structures and mechanics at the portfolio company level helps clarify where your rights begin and end.

The litigation exposure specific to co-investors includes disputes over dilution in subsequent financing rounds, disagreements over exit timing and valuation, and claims arising from the GP's alleged failure to disclose material information about the portfolio company at the time of the co-investment. These claims are harder to pursue than fund-level LP claims because the contractual framework is thinner and the implied covenant of good faith is more difficult to invoke in a purely commercial co-investment context.

Practical protection requires negotiating information rights, anti-dilution provisions, and tag-along rights into the co-investment agreement before closing. After closing, your options narrow considerably.

How the SEC's Regulatory Posture Creates Litigation Exposure for LPs

Regulatory action and private litigation are not independent events in private equity. An SEC enforcement action against a GP frequently precedes or accompanies LP claims pursuing the same factual theories.

The SEC's 2023 Private Fund Rules imposed new disclosure requirements, fairness opinion obligations for GP-led secondaries, and restricted activities requirements on private fund advisers. The Fifth Circuit vacated the rules in June 2024, but the SEC's examination priorities for 2024 make clear that the underlying enforcement concerns, specifically undisclosed conflicts of interest and preferential treatment of certain LPs, remain active. Harvard Law School's corporate governance forum has documented a marked increase in SEC enforcement actions against private fund advisers for exactly these issues.

The practical consequence for LPs is that when the SEC investigates a GP, the resulting record can provide factual support for private litigation claims that would otherwise be difficult to develop through discovery alone. LPs who understand regulatory compliance requirements can use public enforcement records as part of their pre-commitment due diligence.

The SEC's examination priorities also signal where new litigation theories are likely to develop. Fee and expense practices, including undisclosed monitoring fees, transaction fees, and broken deal expenses allocated to the fund, have been a consistent enforcement focus. LPs who have not reviewed their fund's fee offset provisions in light of current SEC guidance may be accepting costs that are legally challengeable.

How to Structure PE Commitments to Minimize Personal Liability Exposure

The question of personal liability is distinct from the question of investment loss. Most LP investors understand that they can lose their committed capital. Fewer think carefully about whether their PE investments create liability that extends beyond that commitment.

Standard LP structure limits your liability to your committed capital. You are not personally liable for fund obligations beyond that amount, provided the fund is properly structured and you have not taken actions that could be characterized as GP-equivalent control. Avoid serving on portfolio company boards in a capacity that creates director-level fiduciary duties unless you have confirmed that D&O coverage extends to you and that the indemnification chain from the portfolio company to the fund to you is intact.

For investors holding multiple fund commitments, consider whether your aggregate exposure to a single GP creates concentration risk that is not just financial but legal. A GP facing significant litigation may have its management company assets at risk, affecting its ability to manage the fund and honor indemnification obligations to LPs who have served in advisory capacities.

Entity structuring matters here. Holding PE commitments through a properly structured LLC or limited partnership can provide an additional layer of protection, though the specifics depend on your jurisdiction and the nature of the investment. This is a conversation for your tax attorney and estate counsel, not a generic recommendation.

Review key stakeholders involved in any fund structure to understand where liability concentrations exist before committing capital.

Litigation Risk Scorecard: Assessing a Fund Manager Before You Commit

Use this framework as a pre-commitment screen. No single factor is disqualifying, but a pattern of red flags across multiple categories warrants a hard look.

A fund scoring red in two or more categories deserves either a renegotiated LP agreement or a pass. The emerging trends in the industry around GP-led secondaries and continuation funds mean that the continuation fund row deserves particular weight for any fund currently in its investment period.

Private Equity Dispute Resolution: What Happens When You Actually Have a Claim

Understanding the resolution pathway before a dispute arises is not pessimism. It is preparation.

Most LP agreements require arbitration for fund-level disputes, typically before JAMS or AAA under Delaware law. Arbitration offers confidentiality, which benefits both parties, but it also limits discovery and eliminates the possibility of a jury. For complex valuation disputes, the arbitration panel's financial sophistication matters enormously. Confirm that your LP agreement allows you to select arbitrators with relevant PE expertise rather than defaulting to a generalist panel.

Pre-litigation negotiation is the most common resolution pathway for LP-GP disputes. GPs have strong incentives to settle before formal proceedings because litigation creates reputational damage, disrupts fundraising for successor funds, and triggers disclosure obligations to other LPs. LPs with credible claims and the resources to pursue them have real leverage at the negotiation table.

If arbitration or litigation becomes unavoidable, the discovery process in PE cases is document-intensive. Financial models, valuation workpapers, internal communications about conflict approvals, and side letter files are all potentially relevant. Preserving your own records of GP communications, capital account statements, and LPAC minutes from the moment a dispute becomes apparent is essential.

Third-party litigation funding has changed the economics for LP claimants. Funders will finance meritorious LP claims in exchange for a portion of the recovery, which means that the cost of pursuing a claim is no longer a barrier for investors who have a strong case but prefer not to deploy capital into litigation. This has increased the volume of LP claims against GPs and shifted the settlement calculus.

The deal process timeline and the specific stage at which a dispute arises will shape which legal theories are available and which limitations periods apply. Breach of fiduciary duty claims in Delaware carry a three-year statute of limitations from the date of the alleged breach, though the discovery rule can toll that period when the breach was concealed.

Emerging Trends in Private Equity Litigation Worth Tracking

The litigation environment is not static. Three developments are reshaping the risk profile for PE investors right now.

ESG-related claims are moving from theoretical to actual. LPs have begun asserting claims against GPs who marketed funds on ESG criteria but failed to implement the stated strategies or misrepresented portfolio company practices. As ESG commitments become more specific and measurable, the gap between marketing language and fund behavior creates actionable claims. Review potential market risks associated with ESG-linked fund structures before committing.

Cross-border enforcement complexity has increased as PE funds operate across multiple jurisdictions with conflicting legal standards. A fund domiciled in Delaware with portfolio companies in Europe and Asia faces potential regulatory action in multiple jurisdictions simultaneously. The enforcement coordination between the SEC, the FCA, and European regulators on private fund governance has improved, which means that a regulatory finding in one jurisdiction can accelerate proceedings in others.

AI and data analytics in litigation are changing discovery economics. Parties can now process millions of documents in weeks rather than years, which reduces the cost advantage that well-resourced GPs historically held over LP claimants. It also means that internal communications that might previously have been buried in discovery are now routinely surfaced. GPs who have been careless in written communications about conflict approvals or valuation decisions face a different risk environment than they did five years ago.

The regulatory trajectory, even post-vacatur of the 2023 Private Fund Rules, points toward more disclosure, more LP rights, and more enforcement. Investors who structure their PE commitments with that trajectory in mind will be better positioned than those who assume the current GP-favorable equilibrium is permanent.

References

• U.S. Securities and Exchange Commission -- "SEC Examination Priorities: Private Fund Advisers" (2024)
• U.S. Securities and Exchange Commission -- "Private Fund Advisers; Documentation of Registered Investment Adviser Compliance Reviews (Final Rule)" (2023)
• Delaware Court of Chancery -- "In re Dell Technologies Inc. Class V Stockholders Litigation" (2022)
• American Bar Association -- "Private Equity and Venture Capital Committee Publications" (Business Law Section)
• Institutional Limited Partners Association (ILPA) -- "ILPA Principles 3.0: Fostering Transparency, Governance, and Alignment of Interests" (2019)
• Preqin -- "Global Private Equity Report" (2024)
• Harvard Law School Forum on Corporate Governance -- "Trends in Private Equity Litigation and Enforcement" (2023)
• Internal Revenue Code -- "IRC Section 1061: Carried Interest Holding Period Rules" (Tax Cuts and Jobs Act)
• Debevoise & Plimpton LLP -- "Private Equity Report (Quarterly)" (2024)
• Evercore -- "Secondary Market Survey" (2023)